Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae

Ryuichiro Abe, Hideharu Hagiya, Yukihiro Akeda, Norihisa Yamamoto, Yoshikazu Ishii, Kazunori Tomono

Research output: Contribution to journalArticle

Abstract

Objective: Carbapenem-resistant Enterobacteriaceae (CRE) are among the most severe threats to public and clinical health because of their high levels of resistance to various antibiotics. We assessed the efficacy of combination therapy with meropenem (MEM) and cefmetazole (CMZ) against Imipenemase (IMP)-producing CRE, using the checkerboard method and time-killing assay on 13 Enterobacteriaceae isolates harboring bla IMP-1 (4 Enterobacter hormaechei, 5 Escherichia coli, and 4 Klebsiella pneumoniae isolates) and 13 isolates harboring bla IMP-6 (8 E. coli and 5 K. pneumoniae isolates). Results: Minimum inhibitory concentrations (MICs) of MEM and CMZ ranged from 2 to 64 and 64 to 2048 μg/mL, respectively. Checkerboard method demonstrated the synergy of the MEM/CMZ combination in all the tested IMP-producing CRE isolates, and the time-kill assay indicated a bactericidal effect for both bla IMP-1 and bla IMP-6 positive CRE when MEM/CMZ combination was used. In vitro, the MEM/CMZ combination was potentially effective against IMP-1- or IMP-6-producing CRE. Further investigations including in vivo animal studies and clinical studies are warranted to corroborate the clinical utility of the novel combination therapy.

Original languageEnglish
Article number740
JournalBMC Research Notes
Volume12
Issue number1
DOIs
Publication statusPublished - Nov 9 2019

Fingerprint

meropenem
Cefmetazole
Carbapenems
Enterobacteriaceae
Escherichia coli
Klebsiella pneumoniae
Assays
Enterobacter
Microbial Sensitivity Tests
Animals
Health
Anti-Bacterial Agents
Public Health

Keywords

  • Carbapenem-resistant Enterobacteriaceae
  • Carbapenemase-producing Enterobacteriacea
  • Cefmetazole
  • Cephamycin
  • IMP

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae. / Abe, Ryuichiro; Hagiya, Hideharu; Akeda, Yukihiro; Yamamoto, Norihisa; Ishii, Yoshikazu; Tomono, Kazunori.

In: BMC Research Notes, Vol. 12, No. 1, 740, 09.11.2019.

Research output: Contribution to journalArticle

Abe, Ryuichiro ; Hagiya, Hideharu ; Akeda, Yukihiro ; Yamamoto, Norihisa ; Ishii, Yoshikazu ; Tomono, Kazunori. / Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae. In: BMC Research Notes. 2019 ; Vol. 12, No. 1.
@article{e4eb91c8d399452d97c75dba6a1b436b,
title = "Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae",
abstract = "Objective: Carbapenem-resistant Enterobacteriaceae (CRE) are among the most severe threats to public and clinical health because of their high levels of resistance to various antibiotics. We assessed the efficacy of combination therapy with meropenem (MEM) and cefmetazole (CMZ) against Imipenemase (IMP)-producing CRE, using the checkerboard method and time-killing assay on 13 Enterobacteriaceae isolates harboring bla IMP-1 (4 Enterobacter hormaechei, 5 Escherichia coli, and 4 Klebsiella pneumoniae isolates) and 13 isolates harboring bla IMP-6 (8 E. coli and 5 K. pneumoniae isolates). Results: Minimum inhibitory concentrations (MICs) of MEM and CMZ ranged from 2 to 64 and 64 to 2048 μg/mL, respectively. Checkerboard method demonstrated the synergy of the MEM/CMZ combination in all the tested IMP-producing CRE isolates, and the time-kill assay indicated a bactericidal effect for both bla IMP-1 and bla IMP-6 positive CRE when MEM/CMZ combination was used. In vitro, the MEM/CMZ combination was potentially effective against IMP-1- or IMP-6-producing CRE. Further investigations including in vivo animal studies and clinical studies are warranted to corroborate the clinical utility of the novel combination therapy.",
keywords = "Carbapenem-resistant Enterobacteriaceae, Carbapenemase-producing Enterobacteriacea, Cefmetazole, Cephamycin, IMP",
author = "Ryuichiro Abe and Hideharu Hagiya and Yukihiro Akeda and Norihisa Yamamoto and Yoshikazu Ishii and Kazunori Tomono",
year = "2019",
month = "11",
day = "9",
doi = "10.1186/s13104-019-4779-x",
language = "English",
volume = "12",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae

AU - Abe, Ryuichiro

AU - Hagiya, Hideharu

AU - Akeda, Yukihiro

AU - Yamamoto, Norihisa

AU - Ishii, Yoshikazu

AU - Tomono, Kazunori

PY - 2019/11/9

Y1 - 2019/11/9

N2 - Objective: Carbapenem-resistant Enterobacteriaceae (CRE) are among the most severe threats to public and clinical health because of their high levels of resistance to various antibiotics. We assessed the efficacy of combination therapy with meropenem (MEM) and cefmetazole (CMZ) against Imipenemase (IMP)-producing CRE, using the checkerboard method and time-killing assay on 13 Enterobacteriaceae isolates harboring bla IMP-1 (4 Enterobacter hormaechei, 5 Escherichia coli, and 4 Klebsiella pneumoniae isolates) and 13 isolates harboring bla IMP-6 (8 E. coli and 5 K. pneumoniae isolates). Results: Minimum inhibitory concentrations (MICs) of MEM and CMZ ranged from 2 to 64 and 64 to 2048 μg/mL, respectively. Checkerboard method demonstrated the synergy of the MEM/CMZ combination in all the tested IMP-producing CRE isolates, and the time-kill assay indicated a bactericidal effect for both bla IMP-1 and bla IMP-6 positive CRE when MEM/CMZ combination was used. In vitro, the MEM/CMZ combination was potentially effective against IMP-1- or IMP-6-producing CRE. Further investigations including in vivo animal studies and clinical studies are warranted to corroborate the clinical utility of the novel combination therapy.

AB - Objective: Carbapenem-resistant Enterobacteriaceae (CRE) are among the most severe threats to public and clinical health because of their high levels of resistance to various antibiotics. We assessed the efficacy of combination therapy with meropenem (MEM) and cefmetazole (CMZ) against Imipenemase (IMP)-producing CRE, using the checkerboard method and time-killing assay on 13 Enterobacteriaceae isolates harboring bla IMP-1 (4 Enterobacter hormaechei, 5 Escherichia coli, and 4 Klebsiella pneumoniae isolates) and 13 isolates harboring bla IMP-6 (8 E. coli and 5 K. pneumoniae isolates). Results: Minimum inhibitory concentrations (MICs) of MEM and CMZ ranged from 2 to 64 and 64 to 2048 μg/mL, respectively. Checkerboard method demonstrated the synergy of the MEM/CMZ combination in all the tested IMP-producing CRE isolates, and the time-kill assay indicated a bactericidal effect for both bla IMP-1 and bla IMP-6 positive CRE when MEM/CMZ combination was used. In vitro, the MEM/CMZ combination was potentially effective against IMP-1- or IMP-6-producing CRE. Further investigations including in vivo animal studies and clinical studies are warranted to corroborate the clinical utility of the novel combination therapy.

KW - Carbapenem-resistant Enterobacteriaceae

KW - Carbapenemase-producing Enterobacteriacea

KW - Cefmetazole

KW - Cephamycin

KW - IMP

UR - http://www.scopus.com/inward/record.url?scp=85074742536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074742536&partnerID=8YFLogxK

U2 - 10.1186/s13104-019-4779-x

DO - 10.1186/s13104-019-4779-x

M3 - Article

C2 - 31706328

AN - SCOPUS:85074742536

VL - 12

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

IS - 1

M1 - 740

ER -